Condition-specific coaching and care AI
CureWise
CureWise is a paid, direct-to-patient AI cancer navigator that consolidates records, explains results, compares Claude, Gemini, and GPT responses, surfaces treatment possibilities, matches clinical trials, and helps patients prepare for oncology conversations. Its patient-chosen design and practical action support are strongly agency-oriented. The main CAIHL cautions are opaque model-provider data flows, non-specific retention, limited output correction and challenge, a trial-count claim that needs clarification, and patient-specific treatment examples that blur the service's educational disclaimer.
Public-source research has been drafted; final human publication review and change-log detail are still required.
Summary judgment · 84% toward patient-directed
Potentially agency-expanding, mixed
CureWise is chosen and paid for by patients and is designed to support understanding, option discovery, and advocacy. The posture remains mixed because high-stakes outputs, external-model data flows, correction routes, trial-match accuracy, and independent validation are not sufficiently public.
Patient agency
How this tool changes agency
Plain-language explanations, record timelines, multi-model comparison, personalized trial discovery, and appointment questions can support patient action. CureWise-specific accuracy, safety, and outcome evidence are not public.
Use is voluntary, includes a seven-day trial, and can be canceled. Public materials say users control sharing, can revoke health-system access, and can request deletion, but the $49 monthly price and unclear downstream model controls limit practical choice.
Patient-facing signals
Who does this AI serve?
Adult patients choose and pay for CureWise and use it with their own records and questions. CureWise's subscription business, record-connectivity partners, and external AI model providers also have interests in the service.
Can patients tell AI is involved?
AI is central to the branding and workflow. CureWise names Claude, Gemini, and GPT, describes AI-generated outputs, and warns that automated answers can be wrong.
Can patients meaningfully choose?
Use is voluntary, includes a seven-day trial, and can be canceled. Public materials say users control sharing, can revoke health-system access, and can request deletion, but the $49 monthly price and unclear downstream model controls limit practical choice.
Can patients correct or challenge what the AI produces?
The privacy policy offers access, correction, deletion, portability, and objection rights for personal data. Public materials do not show how users edit a generated timeline, correct extracted biomarkers or treatment history, dispute a treatment analysis, or challenge a trial match.
Does it help patients understand or act?
Plain-language explanations, record timelines, multi-model comparison, personalized trial discovery, and appointment questions can support patient action. CureWise-specific accuracy, safety, and outcome evidence are not public.
Text findings
Who is left out or burdened?
Subscription, geography, age, language, disability, and digital-access burdens remain
Full use costs $49 per month or $439 per year after a short trial, record connection is U.S.-focused, and accounts are limited to adults. Public sources do not establish multilingual support, financial assistance, accessibility-standard conformance, low-literacy testing, or robust caregiver/proxy controls.
What happens to patient data?
Broad collection and user rights disclosed; AI-provider flows and retention materially opaque
CureWise may process records, labs, genomic/genetic data, images, messages, account/payment data, and usage logs. It says data is not sold, sensitive health data is not used for third-party advertising, and users have access, correction, deletion, restriction, objection, and portability rights. It also claims encryption, role-based access, and audit logging. The policy does not name AI providers, explain Cross-Check context transfer, disclose model-training restrictions, name core subprocessors, or give specific retention periods; terms allow some de-identified or aggregated derivatives to remain after deletion.
Are the clinical boundaries clear?
Clear in legal text, blurred in product examples
CureWise repeatedly says the service is educational, may be inaccurate, and requires clinician confirmation. Its how-it-works example nonetheless gives patient-specific suggestions about restarting a cancer drug, supportive medication, laboratory monitoring, and supplements.
Who defined what good looks like?
Mostly vendor- and founder-defined
Public evidence consists mainly of CureWise materials, founder interviews, launch coverage, patient testimonials, and one clinician testimonial. No CureWise-specific peer-reviewed performance, patient-safety, equity, security, or patient-agency evaluation was identified in this review.
Review method
Public-source review of CureWise product, pricing, privacy, terms, press, and public onboarding surfaces; interview and launch coverage; ClinicalTrials.gov claim comparison; and FDA/FTC context. No paid account, record connection, authenticated workflow test, model/data-flow inspection, vendor interview, patient interview, oncologist review, security audit, accessibility audit, independent validation, or legal/regulatory determination.
Draft profile · Low-to-medium draft, official sources plus interview and launch coverage